AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2023
Sep 6, 2023
31523_dirs_2023-09-06_ceecb5f7-b930-46a3-abf4-1bd1be08bbb0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-09-01
Reporting Person: Campbell Bradley L (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-01 | Common Stock | M | 11700 | $2.94 | Acquired | 810254 | Direct |
| 2023-09-01 | Common Stock | S | 18093 | $12.969 | Disposed | 792161 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-09-01 | Stock Options (right to buy) | $2.94 | M | 11700 | Disposed | 2024-06-26 | Common Stock (11700) | Direct |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.84 to $13.14 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: All of the options were fully vested and exercisable as of the transaction date.